CorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET
Company Participants
Joe Todisco - Chief Executive Officer
Matt David - Executive Vice President, Chief Financial Officer
Erin Mistry - Executive Vice President, Chief Commercial Officer
Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer
Dan Ferry - LifeSci Advisors
Conference Call Participants
Jason Butler - Citizens JMP
Anish Nikhanj - RBC Capital Markets
Lew Sulewski - Truist Securities
Serge Belanger - Needham & Co.
Operator
Good morning ladies and gentlemen, and welcome to the CorMedix Inc. fourth quarter and full year 2023 earnings call.
At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star, zero for the Operator.
This call is being recorded on March 12, 2024.
I would now like to turn the conference over to Dan Ferry from LifeSci Advisors. Please go ahead.
Dan Ferry
Good morning and welcome to the CorMedix full year 2023 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix. He is joined by Dr. Matt David, Executive Vice President and CFO, Beth Zelnick Kaufman, EVP and Chief Legal Officer, Liz Hurlburt, EVP and Chief Clinical Strategy and Operations Officer, and Erin Mistry, EVP and Chief Commercial Officer.
Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include but are not limited to any of the following: any statements other than statements of historical fact regarding management’s expectations, beliefs, goals, and plans about the company’s prospects, including its commercial launch prospects for DefenCath, its clinical development programs for expanded uses of DefenCath, manufacturing activities and marketing approvals for other product candidates, future financial position, future revenues and projected costs, and reimbursement and potential market acceptance of DefenCath or other product candidates.
Actual results may differ materially from these projections or estimates due to a variety of important factors, including but not limited to uncertainties related to clinical development, regulatory approvals, and commercialization. These risks are described in greater detail in CorMedix’s filings with the SEC, including the latest quarterly report on Form 10-Q and annual report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix.